Ryan Recognized as One of the Best Workplaces ™ for Mental Wellness in Canada for the Fifth Time
MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Ryan, a leading global tax services and software provider, has been named to the 2025 Best Workplaces ™ for Mental Wellness in Canada list, marking the fifth time the Firm has received this recognition.
'We are incredibly honored to receive this award, as it reaffirms Ryan's commitment to fostering a workplace where mental wellness is a priority,' said Garry Round, President of Canadian Operations. 'We remain dedicated to championing initiatives that support work-life success and a positive, inclusive culture for all team members.'
Ryan provides a wide range of initiatives that support the health and well-being of its team members. Among them is RyanTHRIVE, a holistic wellness program offering learning modules that address career, financial, and emotional well-being—spanning everything from professional development to building positive relationships.
The Firm also offers competitive benefits designed to promote work-life success, including fitness reimbursements, paid parental leave, tuition assistance, and reimbursement for adoption and fertility programs. These offerings are intentionally designed to ensure every team member feels supported, valued, and equipped with the resources they need throughout their career and life at Ryan.
For additional information on the 2025 Best Workplaces for Mental Wellness in Canada list, visit here.
About Great Place to Work
Great Place to Work is the global authority on high-trust, high-performance workplace cultures. A global research and consulting firm, Great Place to Work provides the benchmarks and expertise needed to create, sustain, and recognize outstanding workplace cultures. In Canada, Great Place to Work produces both industry and demographic-specific Best Workplace lists and represents the voices of 500,000 employees across industry. This is part of the world's largest annual workplace study, recognizing the world's best workplaces in a series of national lists, including those published by The Globe and Mail (Canada) and Fortune ® magazine (USA). Visit us at www.greatplacetowork.ca.
About Ryan
Ryan, an award-winning global tax services and software provider, is the largest Firm in the world dedicated exclusively to business taxes. The Firm provides an integrated suite of federal, provincial, and international tax services on a multijurisdictional basis, including tax recovery, consulting, advocacy, compliance, and technology services. Ryan is an 11-time recipient of the International Service Excellence Award from the Customer Service Institute of America (CSIA) for its commitment to world-class client service. Empowered by the dynamic myRyan work environment, which is widely recognized as the most innovative in the tax services industry, Ryan's multidisciplinary team of more than 5,900 professionals and associates serves over 77,000 clients in more than 80 countries, including many of the world's most prominent Global 5000 companies. More information about Ryan can be found at ryan.com/canada.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Prime Minister to visit Canada for trade and security talks
Prime Minister Sir Keir Starmer will travel to Canada later this week to meet Mark Carney for talks on security and economic partnerships. The Times reported that the pair will meet on June 14, ahead of the G7 leaders' summit in Alberta, against the backdrop of growing concerns about Donald Trump's trade war against its northern neighbour and repeated threats to annex Canada. Mr Trump has repeatedly suggested turning Canada into its 51st state and imposed tariffs that led to retaliation from Ottawa. The Canadian prime minister made the trip to Washington DC last month in a bid to ease tensions, but was dealt a blow last week when the US president doubled tariffs on steel imports. Only the UK was spared from the White House's tariff hike, thanks to a deal struck between the two countries. Levies will remain at 25% for imports from the UK, however Britain could still be subject to the higher 50% rate from July. Sir Keir Starmer's trade pact with the US, struck last month, included relief on the steel and aluminium tariffs, but the implementation is yet to be finalised. The Prime Minister's trip follows a royal visit by the King, who warned Canada is facing a 'critical moment' in its history, with the world a 'more dangerous and uncertain place' in a speech to open the nation's parliament. Charles delivered an address written by the Canadian government that said Mr Carney's administration would bond with 'reliable trading partners and allies', a move that follows Mr Trump's economic tactics. Many Canadians have seen the King's two-day visit to Ottawa as a symbol of support for the nation that has faced the unwanted attention of Mr Trump. Charles told the parliament 'self-determination' was among a number of values Canada held dear and the government was 'determined to protect'.
Wall Street Journal
an hour ago
- Wall Street Journal
Oil Gains Amid Optimism Over U.S.-China Trade Talks
0000 GMT — Oil edges higher in the early Asian session, buoyed by optimism over U.S.-China trade talks that could mitigate risks of tariffs hurting oil demand. President Trump's negotiators sit down with their Chinese counterparts in London later today. Also, supply-side risks are providing extra short- to medium-term support, such as recent wildfires in Canada that threaten production, Saxo Bank's head of Commodity Strategy Ole Hansen says. Front-month WTI crude oil futures are up 0.2% at $64.69/bbl; front-month Brent crude oil futures are 0.2% higher at $66.56/bbl. (
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
